Our Clinical Trials
We are working to redefine the treatment experience of people living with hemophilia using cutting-edge research. Through our preclinical programs and clinical trials, we hope to pave the way for innovative advances in hemophilia management and care that will make a difference for people with hemophilia, healthcare providers, and advocates in the hemophilia community.
Two of our product candidates are in advanced clinical development are:
- Recombinant factor IX (rFIX), IB1001, being investigated for the treatment and prevention of bleeding in people with hemophilia B
- Recombinant porcine factor VIII (rpFVIII), OBI-1, being investigated for the treatment of bleeding in people with acquired hemophilia A and hemophilia A with inhibitors
Our earlier stage, preclinical programs include a recombinant factor VIII (rFVIII) for people with hemophilia A, a recombinant factor VIIa (rFVIIa) for people with hemophilia A or B who have developed inhibitors, and a rFVIIa for people with factor VII deficiency.
If you are interested in the possibility of participating in one of our current or future clinical trials, please mention your interest to your local hemophilia clinic director or physician and ask them to contact us directly.
Please visit www.clinicaltrials.gov to view further information on sites that are currently recruiting
worldwide or plan to participate in future.
IB1001 and OBI-1 are for investigational use only.They have not been reviewed or approved by any regulatory agencies for commercial distribution.